Mineralys Therapeutics Announces Pricing of Upsized Public Offering

Strategic Insights -

Mineralys Therapeutics, a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities, has announced the pricing of an upsized underwritten public offering of 9,803,921 shares of its common stock at a public offering price of $25.50 per share. The aggregate gross proceeds to Mineralys from the offering are expected to be approximately $250.0 million. The company intends to use the net proceeds to fund clinical development of its lead product candidate, lorundrostat, including research and development and manufacturing, and pre-commercialization activities.

Key Takeaways:

  • Mineralys Therapeutics has priced an upsized public offering of 9,803,921 shares of its common stock at $25.50 per share, raising approximately $250.0 million in gross proceeds.
  • The company plans to use the net proceeds from the offering to fund clinical development of lorundrostat, including research and development, manufacturing, and pre-commercialization activities.
  • Lorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor, the company's initial product candidate for treating hypertension and related comorbidities.
  • The biopharmaceutical company, based in Radnor, Pennsylvania, is focused on developing medicines to target diseases driven by dysregulated aldosterone, including chronic kidney disease, obstructive sleep apnea, and other comorbidities.
  • The proposed public offering is being conducted under a shelf registration statement previously filed and declared effective by the Securities and Exchange Commission.

Statistics:

  • 9,803,921 shares of Mineralys' common stock were offered at a public offering price of $25.50 per share.
  • The aggregate gross proceeds from the offering are expected to be approximately $250.0 million.
  • Mineralys intends to use the net proceeds primarily for the development of lorundrostat, and the company's representatives estimate that the net proceeds will be approximately $230-240 million, assuming the underwriters do not exercise their option to purchase additional shares.
  • The company plans to use the net proceeds for working capital and general corporate purposes.

Sources:

  • GlobeNewswire, "Mineralys Therapeutics, Inc. Announces Pricing of Upsized Public Offering" (September 2, 2025)
  • SEC EDGAR database, company press release (September 2, 2025)